利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.014 秒)

    DEVICE, SYSTEM AND METHOD FOR IN-VIVO ANALYSIS
    2.
    发明申请
    DEVICE, SYSTEM AND METHOD FOR IN-VIVO ANALYSIS 审中-公开
    用于体内分析的装置，系统和方法

    公开(公告)号：US20110092768A1

    公开(公告)日：2011-04-21

    申请号：US12740764

    申请日：2008-11-02

    申请人： Noam Emanuel ,  Emil-Israel Katz ,  Elena Khazanov ,  Abraham Rubinstein ,  Yechezkel Barenholz ,  Abdel Kareem Azab

    发明人： Noam Emanuel ,  Emil-Israel Katz ,  Elena Khazanov ,  Abraham Rubinstein ,  Yechezkel Barenholz ,  Abdel Kareem Azab

    IPC分类号： A61B1/04 ,  B05D1/36 ,  B05D5/00

    CPC分类号： A61B1/041

    摘要： A device for in-vivo detection comprises a housing having an optical window and enclosing an imager that is configured to image the optical window. An external surface of the optical window has trypsin immobilized thereon, and may also be coated with a steric barrier protection, which may be polyethylene glycol (PEG). A trypsin-Alpha-1-antitrypsin complex formed on the window may have an affinity to a binding agent, which is tagged by a tag selected from a group consisting of a colorant, a fluorescent moiety, and a radioactive moiety.

    摘要翻译： 用于体内检测的装置包括具有光学窗口并且包围被配置成对光学窗口成像的成像器的壳体。 光学窗口的外表面具有固定在其上的胰蛋白酶，并且还可以涂覆有空间屏障保护，其可以是聚乙二醇（PEG）。 形成在窗户上的胰蛋白酶-β-1-抗胰蛋白酶复合物可以对结合剂具有亲和性，所述结合剂由选自着色剂，荧光部分和放射性部分的标签标记。

    Controlled release oral drug delivery system
    3.
    发明授权
    Controlled release oral drug delivery system 失效
    控制释放口服药物输送系统

    公开(公告)号：US07189414B2

    公开(公告)日：2007-03-13

    申请号：US10630917

    申请日：2003-07-31

    申请人： Abraham Rubinstein ,  Michael Friedman ,  Muhammad Baluom ,  Boaz Tirosh

    发明人： Abraham Rubinstein ,  Michael Friedman ,  Muhammad Baluom ,  Boaz Tirosh

    IPC分类号： A61K9/10 ,  A61K9/22 ,  A61K47/32 ,  A61K47/38

    CPC分类号： A61K9/2027 ,  A61K9/2013 ,  Y10S514/944 ,  Y10S514/946

    摘要： The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation,wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and/or the agent which inhibits intestinal drug degradation.

    摘要翻译： 本发明涉及包含聚合物基质的同步药物递送组合物，其包含与疏水性聚合物共混的水凝胶，以形成可溶性基质，药物和任选的增强肠药物吸收的试剂和/或抑制 肠道药物降解，其中可侵蚀基质的侵蚀允许药物，水凝胶和肠药物吸收剂和/或抑制肠药物降解的试剂的同步释放。

    Controlled release oral drug delivery system
    6.
    发明授权
    Controlled release oral drug delivery system 失效
    控制释放口服药物输送系统

    公开(公告)号：US06692766B1

    公开(公告)日：2004-02-17

    申请号：US08750674

    申请日：1997-02-28

    申请人： Abraham Rubinstein ,  Raphael Radai ,  Michael Friedman ,  Boaz Tirosh ,  Muhammad Baluom ,  Taher Nassar

    发明人： Abraham Rubinstein ,  Raphael Radai ,  Michael Friedman ,  Boaz Tirosh ,  Muhammad Baluom ,  Taher Nassar

    IPC分类号： A61K910

    CPC分类号： A61K9/2027 ,  A61K9/2013 ,  Y10S514/944 ,  Y10S514/946

    摘要： The present invention relates to a controlled release drug delivery system comprising a drug which is susceptible to enzymatic degradation by enzymes present in the intestinal tract; and a polymeric matrix which undergoes erosion in the gastrointestinal tract comprising a hydrogel-forming polymer selected from the group consisting of (a) polymers which are themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inbihiting degradation of said drug by intestinal enzymes; and (b) polymers which are not themselves capable of enhancing absorption of said drug across the intestinal mucosal tissues and of inhibiting degradation of said drug by intestinal enzymes; wherein when the matrix comprises a polymer belonging to group (b) the delivery system further comprises an agent which enhances absorption of said drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of said drug by intestinal enzymes and when the matrix comprises a polymer belonging to group (a) the delivery system optionally further comprises an agent which enhances absorption of said drug across the intestinal mucosal tissues and/or an agent which inhibits degradation of said drug by intestinal enzymes.

    摘要翻译： 本发明涉及一种控释药物递送系统，其包含易于通过存在于肠道中的酶进行酶降解的药物; 以及在胃肠道中遭受侵蚀的聚合物基质，其包含选自以下的水凝胶形成性聚合物：（a）本身能够增强所述药物穿过肠粘膜组织的吸收的聚合物和所述药物的不利因素降解 肠酶; 和（b）本身不能增强所述药物穿过肠粘膜组织的吸收并且通过肠酶抑制所述药物降解的聚合物; 其中当所述基质包含属于组（b）的聚合物时，所述递送系统还包含增强所述药物穿过肠粘膜组织的吸收的试剂和/或通过肠酶抑制所述药物降解的药剂，并且当所述基质包含 属于（a）组的聚合物任选地还包含增强所述药物穿过肠粘膜组织的吸收的试剂和/或通过肠酶抑制所述药物降解的试剂。

    Method for Selecting Cationic or Anionic Liposomes for Treatment of a Mucosa Membrane, and Kit Comprising the Same
    7.
    发明申请
    Method for Selecting Cationic or Anionic Liposomes for Treatment of a Mucosa Membrane, and Kit Comprising the Same 审中-公开
    用于选择阳离子或阴离子脂质体用于治疗粘膜膜的方法，以及包含它的试剂盒

    公开(公告)号：US20070212403A1

    公开(公告)日：2007-09-13

    申请号：US10578090

    申请日：2004-11-03

    申请人： Yechezkel Barenholz ,  Abraham Rubinstein ,  Tareq Jubeh

    发明人： Yechezkel Barenholz ,  Abraham Rubinstein ,  Tareq Jubeh

    IPC分类号： A61K9/127

    CPC分类号： A61K9/1272 ,  A61K9/127

    摘要： The present invention is based on the use of electrical surface charge as a docking tool to bring charged lipid assemblies in the vicinity of a diseased, e.g. inflamed epithelium of the mucosa, or alternatively, to a normal epithelium, for executing a desired medical procedure. Thus, the present invention provides a method for selecting a medicament for a medical procedure has now been designed. The medical procedure is selected from treatment, for the healing of a disease or disorder of a mucosa, prophylaxis of a disease or disorder or a mucosa, or a combination of same. The method steps are based on the observation that there are differences in the attachment properties of charged lipid assemblies, such as liposomes, when examined in healthy or inflamed mucosal tissues. The invention also provides a kit making use of the method of the invention. Yet, the invention concerns a method and a medicament for the treatment or prevention of a disease or disorder of the gastrointestinal mucosa, as well as the use of charged lipid assemblies for obtaining said medicament, based on the principles of the differential adhesion of positively vs. negatively charged lipid assemblies to healthy and diseased mucosa, respectively.

    摘要翻译： 本发明基于使用电表面电荷作为对接工具，以使带电的脂质组件在患病的附近，例如， 粘膜的发炎的上皮，或者替代地，用于正常的上皮，用于执行所需的医疗程序。 因此，本发明提供了一种用于选择用于医疗程序的药物的方法。 医疗程序选自治疗，治疗粘膜疾病或病症，预防疾病或病症或粘膜，或其组合。 方法步骤基于观察，当在健康或发炎的粘膜组织中检查时，带电脂质组件（例如脂质体）的附着性质存在差异。 本发明还提供了使用本发明方法的试剂盒。 然而，本发明涉及用于治疗或预防胃肠粘膜疾病或病症的方法和药物，以及用于获得所述药物的带电脂质组合物的用途，基于差异粘附的原则 带负电荷的脂质组件分别为健康和患病的粘膜。

    Colonic drug delivery system
    8.
    发明授权
    Colonic drug delivery system 失效
    结肠给药系统

    公开(公告)号：US5866619A

    公开(公告)日：1999-02-02

    申请号：US969706

    申请日：1997-11-26

    申请人： Amnon Sintov ,  Abraham Rubinstein

    发明人： Amnon Sintov ,  Abraham Rubinstein

    IPC分类号： A61K9/20 ,  A61K9/22 ,  C08B37/00 ,  A61K9/48 ,  A61K9/36 ,  A61K9/50 ,  A61K9/64

    CPC分类号： A61K9/205 ,  A61K9/2027 ,  C08B37/0045 ,  C08B37/0069 ,  Y10S514/96 ,  Y10S514/965

    摘要： A colonic delivery system for delivering a drug to the colon is provided. The system comprises a drug in combination with a matrix, wherein the matrix comprises a saccharide-containing polymer. According to the invention, the matrix is resistant to chemical and enzymatic degradation in the stomach and small intestine. The matrix is degraded in the colon by bacterial enzymatic action, and the drug is released. The system is useful for targeting drugs to the colon in order to treat colonic disease. The system is also useful for enteric administration of drugs such as proteins and peptides which are otherwise degraded in the stomach and small intestine.

    摘要翻译： 提供了用于将药物递送至结肠的结肠递送系统。 该系统包括与基质组合的药物，其中基质包含含糖聚合物。 根据本发明，该基质耐胃和小肠中的化学和酶降解。 基质通过细菌酶作用在结肠中降解，药物释放。 该系统用于将药物靶向结肠以治疗结肠疾病。 该系统还可用于肠内给药，例如蛋白质和肽，否则其在胃和小肠中降解。